A Phase II Study of Concurrent Stereotactic Body Radiotherapy With Ipilimumab and Nivolumab in Patients With Metastatic Uveal Melanoma
Latest Information Update: 08 Dec 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions
- 19 Oct 2021 New trial record